ERRATUM

Erratum to: Symptomatic and Palliative Care for Stroke Survivors

Claire J. Creutzfeldt, MD¹, Robert G. Holloway, MD, MPH^{2,3}, and Melanie Walker, MD¹

¹Department of Neurology, University of Washington Harborview Medical Center, Seattle, WA, USA; ²Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA; ³Department of Medicine, Division of Palliative Care, University of Rochester Medical Center, Rochester, NY, USA.

J Gen Intern Med 29(12):1715

DOI: 10.1007/s11606-014-2876-z

© Society of General Internal Medicine 2014

Erratum to: J Gen Intern Med

DOI: 10.1007/s11606-011-1966-4

On page 857 of the original publication, the following statement contains a technical error.

Recently, the FDA approved Nuedexta, a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis or multiple sclerosis.

Correction: Although the FDA approved Nuedexta based on studies in AML and MS, the approved indication was for treatment of pseudobulbar palsy (without restriction to a specific underlying condition).

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11606-011-1966-4>.

Published online May 24, 2014